WO1996039391B1 - Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation - Google Patents
Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferationInfo
- Publication number
- WO1996039391B1 WO1996039391B1 PCT/US1996/008375 US9608375W WO9639391B1 WO 1996039391 B1 WO1996039391 B1 WO 1996039391B1 US 9608375 W US9608375 W US 9608375W WO 9639391 B1 WO9639391 B1 WO 9639391B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- compound
- hydrogen
- alkyl
- pharmaceutically acceptable
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title claims abstract 8
- 210000000329 smooth muscle myocyte Anatomy 0.000 title claims abstract 8
- 239000003112 inhibitor Substances 0.000 title abstract 2
- QQLPPRIZUPEKMV-UHFFFAOYSA-N 2-(2-phenylethenyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1C=CC1=CC=CC=C1 QQLPPRIZUPEKMV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 29
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 27
- 239000001257 hydrogen Substances 0.000 claims abstract 27
- 125000000217 alkyl group Chemical group 0.000 claims abstract 20
- 150000002431 hydrogen Chemical class 0.000 claims abstract 20
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 16
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract 10
- 150000002367 halogens Chemical class 0.000 claims abstract 10
- -1 nitro, carboxyl Chemical group 0.000 claims abstract 9
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims abstract 7
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000002541 furyl group Chemical group 0.000 claims abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 5
- 125000003118 aryl group Chemical group 0.000 claims abstract 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 53
- 241000124008 Mammalia Species 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 238000002399 angioplasty Methods 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- GQIFVGIZDNGSCZ-CSKARUKUSA-N 2-[(e)-2-(3,4-dimethoxyphenyl)ethenyl]-1h-benzimidazole Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C1=NC2=CC=CC=C2N1 GQIFVGIZDNGSCZ-CSKARUKUSA-N 0.000 claims 1
- RBGOSUBTEIUSSA-XBXARRHUSA-N 2-[(e)-2-(3,4-dimethoxyphenyl)ethenyl]-3h-benzimidazole-5-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C1=NC2=CC(C(O)=O)=CC=C2N1 RBGOSUBTEIUSSA-XBXARRHUSA-N 0.000 claims 1
- VEIKFDKHUBMRBI-XBXARRHUSA-N 2-[(e)-2-(3,4-dimethoxyphenyl)ethenyl]-6-nitro-1h-benzimidazole Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C1=NC2=CC=C([N+]([O-])=O)C=C2N1 VEIKFDKHUBMRBI-XBXARRHUSA-N 0.000 claims 1
- ZUMIBXPTGMOQDK-UHFFFAOYSA-N 2-[2-(2,4-dichlorophenyl)ethenyl]-1h-benzimidazole Chemical group ClC1=CC(Cl)=CC=C1C=CC1=NC2=CC=CC=C2N1 ZUMIBXPTGMOQDK-UHFFFAOYSA-N 0.000 claims 1
- GQIFVGIZDNGSCZ-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethenyl]-1h-benzimidazole Chemical compound C1=C(OC)C(OC)=CC=C1C=CC1=NC2=CC=CC=C2N1 GQIFVGIZDNGSCZ-UHFFFAOYSA-N 0.000 claims 1
- LCBMHTYNXWUSPE-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethenyl]-4,7-dimethoxy-5,6-dimethyl-1h-benzimidazole Chemical compound C1=C(OC)C(OC)=CC=C1C=CC1=NC2=C(OC)C(C)=C(C)C(OC)=C2N1 LCBMHTYNXWUSPE-UHFFFAOYSA-N 0.000 claims 1
- FMNIIPCIVIAMRR-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethenyl]-5,6-dimethyl-1h-benzimidazole-4,7-dione Chemical compound C1=C(OC)C(OC)=CC=C1C=CC1=NC(C(C(C)=C(C)C2=O)=O)=C2N1 FMNIIPCIVIAMRR-UHFFFAOYSA-N 0.000 claims 1
- DWRQQZSAQGSHFJ-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethenyl]-6-methoxy-1h-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1C=CC1=CC=C(OC)C(OC)=C1 DWRQQZSAQGSHFJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- XTAPZTRJPVKGEV-DAFODLJHSA-N 6-nitro-2-[(e)-2-pyridin-4-ylethenyl]-1h-benzimidazole Chemical compound N=1C2=CC([N+](=O)[O-])=CC=C2NC=1\C=C\C1=CC=NC=C1 XTAPZTRJPVKGEV-DAFODLJHSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VZFYIURHZDVBMS-WEVVVXLNSA-N methyl 2-[(e)-2-(3,4-dimethoxyphenyl)ethenyl]-3h-benzimidazole-5-carboxylate Chemical compound N=1C2=CC(C(=O)OC)=CC=C2NC=1\C=C\C1=CC=C(OC)C(OC)=C1 VZFYIURHZDVBMS-WEVVVXLNSA-N 0.000 claims 1
- GDBDEXWEXJJQCV-UHFFFAOYSA-N methyl 4-[[2-[2-(3,4-dimethoxyphenyl)ethenyl]-4,7-dimethoxy-5,6-dimethylbenzimidazol-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C2=C(OC)C(C)=C(C)C(OC)=C2N=C1C=CC1=CC=C(OC)C(OC)=C1 GDBDEXWEXJJQCV-UHFFFAOYSA-N 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Abstract
Disclosed herein are compounds of formula (I) or (II), wherein R is phenyl or substituted phenyl; or R is furyl, pyridyl or quinolinyl; R1 and R2 are hydrogen, halogen, alkyl, alkoxy, nitro, carboxyl, alkoxycarbonyl or aryloxycarbonyl; R3 is hydrogen, alkyl, aryl or arylalkyl; R4 and R5 are hydrogen or alkyl; or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of smooth muscle cell proliferation.
Claims
-28-
AMENDED CLAIMS
[received by the International Bureau on 27 November 1996 (27.11.96); original claims 1-27 replaced by amended claims 1-23 (6 pages)]
( 1 ) A compound of formula I or II:
wherein R is furyl, pyridyl, phenyl or phenyl substituted with alkoxy of 1 to 6 carbon atoms; Ri and R2 are hydrogen, alkoxy of 1 to 6 carbon atoms, nitro, carboxyl, alkoxycarbonyl of 2 to 7 carbon atoms or aryloxycarbonyl of 7 to 12 carbon atoms; R3 is hydrogen or benzyl substituted with alkoxycarbonyl of 2 to 6 carbon atoms; and R4 and R5 are hydrogen or methyl; provided that in formula I when Ri, R2 and R3 are hydrogen, R is not phenyl, 2- methoxyphenyl, 3-methoxyphenyl, 4- methoxyphenyl, 2,3-dimethoxyphenyl, 3,4,5- trimethoxyphenyl or 4-ethoxyphenyl, pyridyl, fur-2-yl or furan-3-yl, and provided that the compound of formula I is not 2-[2-(3,4-dimethoxyphenyl)-vinyl]-lH- benzoimidazole.
(2) A compound of formula I which is
wherein
Rl and R2 are hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, nitro, carboxyl, alkoxycarbonyl of 2 to 7 carbon atoms or aryloxycarbonyl of 7 to 12 carbon atoms; provided R1 and R2 is not nitro when the other is hydrogen, or a pharmaceutically acceptable salt thereof.
(3) A compound which is (E)-2-[2-(3,4-dimethoxyphenyl)-vinyl]-lH- benzoimidazole or a pharmaceutically acceptable salt thereof.
(4) A compound which is 2-[2-(3,4-dimethoxyphenyl)-vinyl]-5-methoxy-lH- benzoimidazole or a pharmaceutically acceptable salt thereof.
(5) A compound which is { 2-[2-(3 .-dimetk axyphenyl)- vinyl]- lH-benzoimidazol-5- yl} -pheny 1-methanone or a pharmaceutically acceptable salt thereof.
(6) A compound which is 2-[2-(3,4-dimethoxyphenyl)-vinyl]-4,7-dimethoxy-5,6- dimethyl-lH-benzoimidazole or a pharmaceutically acceptable salt thereof.
(7) A compound which is (E)-2-[2-(3,4-dimethoxyphenyl)-vinyl]-lH- benzoimidazole-5-carboxylic acid methyl ester or a pharmaceutically acceptable salt thereof.
(8) A compound which is (E)-2-[2-(3,4-dimethoxyphenyl)-vinyl]-lH- benzoimidazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof.
(9) A compound which is (E)-2-[2-(3,4-dimethoxyphenyl)-vinyl]-5-nitro-lH- benzoimidazole or a pharmaceutically acceptable salt thereof.
(10) A compound which is 4-{2-[2-(3,4-dimethoxyphenyl)-vinyl]-4,7-dimethoxy-5,6- dimethylbenzoimidazol-1 -ylmethyl} -benzoic acid methyl ester or a pharmaceutically acceptable salt thereof.
(11) A compound which is 2-[2-(3,4-dimethoxyphenyl)- vinyl] -5,6-dimethyl- 1H- benzoimidazol-4,7-dione or a pharmaceutically acceptable salt thereof.
(12) A compound which is (E)-5-nitro2-(2-pyridin-4-yl-vinyl)-lH-benzoimidazole or a pharmaceutically acceptable salt thereof.
(13) A compound which is (E)-2-(2-furan-3-yl-vinyl)-5-nitiO-lH-benzoimidazole or a pharmaceutically acceptable salt thereof.
(14) A compound of formula I or II:
wherein
R is phenyl or phenyl substituted with halogen, hydroxyl, alkoxy of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, trifluoromethyl, or R is furyl, pyridyl or quinolinyl; Rl and R2 are hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, nitro, carboxyl, alkoxycarbonyl of 2 to 7 carbon atoms or aryloxycarbonyl of 7 to 12 carbon atoms; R3 is hydrogen, alkyl of 1 to 6 carbon atoms, aryl of 6 to 12 carbon atoms or arylalkyl of 7 to 12 carbon atoms optionally substituted with alkoxycarbonyl of 2 to 6 carbon atoms; R4 and R5 are hydrogen or alkyl of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof, provided that when R is substituted phenyl and one of R 1 or R2 is hydrogen, chlorine or nitro and the other is hydrogen, then R3 is not hydrogen, methyl or benzyl, and provided that when R3 is benzyl, R is not 2, 4-dichlorostyryl benzimidazole, and provided that when R is phenyl, Ri, R2 and R3 are not all hydrogen, and provided that when R\ or R2 is H, nitro or chloro and R3 is hydrogen, then R is not chloro-substituted phenyl, and provided that when one of Ri or R2 is bromo and R3 is hydrogen, then R is not phenyl; for use in the treatment of mammals.
(15) A compound as claimed in claim 14 for use in the treatment of diseases or conditions related to smooth muscle cell proliferation.
(16) A compound according to claim 15 wherein said smooth muscle cell proliferation manifests itself as restenosis following angioplasty.
(17) Use of a compound of formula I or II:
-31
wherein
R is phenyl or phenyl substituted with halogen, hydroxyl, alkoxy of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, trifluoromethyl, or R is furyl, pyridyl or quinolinyl; Rl and R2 are hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, nitro, carboxyl, alkoxycarbonyl of 2 to 7 carbon atoms or aryloxycarbonyl of 7 to 12 carbon atoms; R3 is hydrogen, alkyl of 1 to 6 carbon atoms, aryl of 6 to 12 carbon atoms or arylalkyl of 7 to 12 carbon atoms optionally substituted with alkoxycarbonyl of 2 to 6 carbon atoms; R4 and R5 are hydrogen or alkyl of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of smooth muscle cell proliferation in a mammal .
(18) Use of a compound according to claim 17 wherein said smooth muscle cell proliferation manifests itself as restenosis following angioplasty.
(19) A pharmaceutical composition comprising a compound of formula I or II according to any of claims 1 to 16 and a pharmaceutically acceptable carrier.
(20) A method for treatment of a mammal which comprises administering to that mammal, orally or parenterally, a compound of formula I or II:
wherein
-32-
R is phenyl or phenyl substituted with halogen, hydroxyl, alkoxy of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, trifluoromethyl, or R is furyl, pyridyl or quinolinyl; Rl and R2 are hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, nitro, carboxyl, a'-coxycarbonyl of 2 to 7 carbon atoms or aryloxycarbonyl of 7 to 12 carbon atoms; R3 is hydrogen, alkyl of 1 to 6 carbon atoms, aryl of 6 to 12 carbon atoms or arylalkyl of 7 to 12 carbon atoms optionally substituted with alkoxycarbonyl of 2 to 6 carbon atoms; R4 and R5 are hydrogen or alkyl of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof.
(21) A method according to claim 20 for preventing smooth muscle cell proliferation in mammals.
(22) A method according to claim 21 in which the smooth muscle cell proliferation manifests itself as restenosis following angioplasty.
(23) A process for the preparation of a compound of formula I or II:
wherein
R is phenyl or phenyl substituted with halogen, hydroxyl, alkoxy of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, trifluoromethyl, or R is furyl, pyridyl or quinolinyl; Rl and R2 are hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, nitro, carboxyl, alkoxycarbonyl of 2 to 7 carbon atoms or aryloxycarbonyl of 7 to 12 carbon atoms; R3 is hydrogen, alkyl of 1 to 6 carbon atoms, aryl of 6 to 12 carbon atoms or arylalkyl of
7 to 12 carbon atoms optionally substituted with alkoxycarbonyl of 2 to 6 carbon atoms; R4 and R5 are hydrogen or alkyl of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof, which comprises:
-33-
(a) reacting a nitrile of formula 1
R' .CN
1 with an alcohol and hydrogen chloride to form the compound of formula 2:
NH
R ',V^OMe - HCl
2
(b) reacting the compound of formula 2 with a compound of formula 3:
3 in the presence of an alcohol to form the compound of formula 4:
4
(c) reacting the compound of formula 4 with R3 -halide in the presence of an alkylating agent to form the compound of formula I:
(d) and optionally reacting 5:
5 with (NHU)2Ce(N)3)6 in the presence of acetic acid to form the compound of formula II:
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT96916978T ATE205196T1 (en) | 1995-06-06 | 1996-06-03 | STYRYLBENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION |
| BR9609153A BR9609153A (en) | 1995-06-06 | 1996-06-03 | Styrene-benzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
| NZ309499A NZ309499A (en) | 1995-06-06 | 1996-06-03 | Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation |
| DE69615023T DE69615023T2 (en) | 1995-06-06 | 1996-06-03 | STYRYLBENE IMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROPELLATION |
| EP96916978A EP0830345B1 (en) | 1995-06-06 | 1996-06-03 | Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
| JP9500994A JPH11506753A (en) | 1995-06-06 | 1996-06-03 | Styrylbenzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
| DK96916978T DK0830345T3 (en) | 1995-06-06 | 1996-06-03 | Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
| AU59684/96A AU711965B2 (en) | 1995-06-06 | 1996-06-03 | Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/468,271 US6444694B1 (en) | 1995-06-06 | 1995-06-06 | Styryl benzimidazole derivatives |
| US08/468,271 | 1995-06-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996039391A1 WO1996039391A1 (en) | 1996-12-12 |
| WO1996039391B1 true WO1996039391B1 (en) | 1997-01-09 |
Family
ID=23859136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/008375 WO1996039391A1 (en) | 1995-06-06 | 1996-06-03 | Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6444694B1 (en) |
| EP (1) | EP0830345B1 (en) |
| JP (1) | JPH11506753A (en) |
| KR (1) | KR19990022266A (en) |
| CN (1) | CN1192206A (en) |
| AR (1) | AR002749A1 (en) |
| AT (1) | ATE205196T1 (en) |
| AU (1) | AU711965B2 (en) |
| BR (1) | BR9609153A (en) |
| CA (1) | CA2223585A1 (en) |
| DE (1) | DE69615023T2 (en) |
| DK (1) | DK0830345T3 (en) |
| ES (1) | ES2162063T3 (en) |
| HU (2) | HUP9900914A2 (en) |
| IL (1) | IL118385A0 (en) |
| NZ (1) | NZ309499A (en) |
| PT (1) | PT830345E (en) |
| WO (1) | WO1996039391A1 (en) |
| ZA (1) | ZA964693B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| KR20120091276A (en) | 2004-02-20 | 2012-08-17 | 베링거 인겔하임 인터내셔날 게엠베하 | Viral polymerase inhibitors |
| EP1915378A4 (en) | 2005-08-12 | 2009-07-22 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| CA2656851C (en) | 2006-07-05 | 2013-12-10 | Fibrotech Therapeutics Pty Ltd | Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity |
| US9062076B2 (en) | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| EP3577103A1 (en) | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
| KR102853258B1 (en) * | 2023-06-20 | 2025-09-01 | 이원다이애그노믹스(주) | Novel compound, preparation method thereof and pharmaceutical composition for preventing and treating cancer as active ingredient |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3575956A (en) * | 1967-07-24 | 1971-04-20 | Sterling Drug Inc | 2-substituted-benz-x-azol-6-ylazo-aminonaphthalene compounds |
| DE1670908A1 (en) * | 1967-08-16 | 1971-04-29 | Hoechst Ag | Novel benzimidazole compounds, processes for their preparation and their use as optical brightening agents |
| FR2104717A1 (en) * | 1970-09-28 | 1972-04-21 | Dynachim Sarl | Organophosphorus pesticides stabilised with benzimidazole derivs - - for controlling insects and internal parasites of animals |
| DE3505609A1 (en) | 1985-02-19 | 1986-08-21 | Merck Patent Gmbh, 6100 Darmstadt | BENZIMIDAZOLYL PYRIDAZINONE |
| US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| WO1991016305A1 (en) | 1990-04-16 | 1991-10-31 | Rhone-Poulenc Rorer International (Holdings), Inc. | Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase |
| DE4212748A1 (en) | 1992-04-16 | 1993-10-21 | Thomae Gmbh Dr K | New 1-bi:phenyl:methyl- benzimidazole derivs. - used as angiotensin antagonists, e.g. for treating cardiovascular, pulmonary and CNS disorders e.g. Alzheimer's disease, ischaemia etc. |
| US5387600A (en) | 1992-07-30 | 1995-02-07 | Fuji Photo Film Co., Ltd. | Treating arteriosclerosis using benzimidazole compositions |
-
1995
- 1995-06-06 US US08/468,271 patent/US6444694B1/en not_active Expired - Fee Related
-
1996
- 1996-05-22 IL IL11838596A patent/IL118385A0/en unknown
- 1996-05-30 AR ARP960102799A patent/AR002749A1/en unknown
- 1996-06-03 PT PT96916978T patent/PT830345E/en unknown
- 1996-06-03 CN CN96195860A patent/CN1192206A/en active Pending
- 1996-06-03 KR KR1019970708745A patent/KR19990022266A/en not_active Withdrawn
- 1996-06-03 HU HU9900914A patent/HUP9900914A2/en unknown
- 1996-06-03 DE DE69615023T patent/DE69615023T2/en not_active Expired - Fee Related
- 1996-06-03 AT AT96916978T patent/ATE205196T1/en not_active IP Right Cessation
- 1996-06-03 AU AU59684/96A patent/AU711965B2/en not_active Ceased
- 1996-06-03 HU HU9900679A patent/HUP9900679A3/en unknown
- 1996-06-03 BR BR9609153A patent/BR9609153A/en unknown
- 1996-06-03 JP JP9500994A patent/JPH11506753A/en active Pending
- 1996-06-03 NZ NZ309499A patent/NZ309499A/en unknown
- 1996-06-03 ES ES96916978T patent/ES2162063T3/en not_active Expired - Lifetime
- 1996-06-03 CA CA002223585A patent/CA2223585A1/en not_active Abandoned
- 1996-06-03 DK DK96916978T patent/DK0830345T3/en active
- 1996-06-03 WO PCT/US1996/008375 patent/WO1996039391A1/en not_active Application Discontinuation
- 1996-06-03 EP EP96916978A patent/EP0830345B1/en not_active Expired - Lifetime
- 1996-06-05 ZA ZA9604693A patent/ZA964693B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003272979B2 (en) | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | |
| RU2203894C2 (en) | Novel derivatives of pyrimidine (variants) | |
| CA2291630A1 (en) | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | |
| WO1996039391B1 (en) | Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation | |
| DK0793656T3 (en) | New benzyl pyrimidines | |
| KR930701415A (en) | Pharmaceutically Active Benzoquinazolin Compounds | |
| RU2003127733A (en) | METALLOPROTEINASE INHIBITORS | |
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| CN1152870A (en) | Use of heterocyclic compounds as dopamine D3 ligands | |
| FI963238A0 (en) | Heteroaromatic oxazole compounds and their use | |
| JP2002516277A5 (en) | ||
| MEP61208A (en) | Novel compounds having inhibitory activity against sodium-dependant transporter | |
| CA2217952A1 (en) | A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers | |
| NO820340L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOLE DERIVATIVES | |
| EP1566378A1 (en) | Isoindoline derivative | |
| NO20055655D0 (en) | Use of azetidinecarboxamide derivatives in therapy | |
| IL42841A (en) | 2-(anilinomethyl)morpholine derivatives | |
| JP2004521150A5 (en) | ||
| JP2003514893A5 (en) | ||
| RU2005108586A (en) | 3,4-DISPLACED PYRROLES AND THEIR APPLICATION FOR TREATMENT OF INFLAMMATORY DISEASES | |
| NZ309499A (en) | Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation | |
| CN1130381A (en) | Use of coumarins and carbostyrils as PLAZ inhibitors, new coumarins and carbostyrils, process for prep, the same and medicaments | |
| CA2374158A1 (en) | Indole derivatives | |
| JP2002514623A5 (en) | ||
| BR0107404A (en) | Indole derivatives that act as mcp-1 receptor antagonists |